Evidence map›Paper›PMID 35431779›Full record

ReviewFrontiers in neuroscience2022

Recent Advances in the Modeling of Alzheimer's Disease.

Hiroki Sasaguri, Shoko Hashimoto, Naoto Watamura, Kaori Sato, Risa Takamura, Kenichi Nagata, Satoshi Tsubuki, Toshio Ohshima, Atsushi Yoshiki, Kenya Sato and 8 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 155 citations in OpenAlex.

  1. Article
  2. Progressive behavioral and cognitive decline inbioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Nanoscopic Mapping of the Extracellular Space in Amyloid Plaque-rich Cortex.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. The Role of Neprilysin and Insulin-Degrading Enzyme in the Etiology of Sporadic Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  18. Article
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 2 countries.

Hiroki SasaguriLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Shoko HashimotoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Naoto WatamuraLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Kaori SatoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Risa TakamuraLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Kenichi NagataDepartment of Functional Anatomy and Neuroscience, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Satoshi TsubukiLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Toshio OhshimaLaboratory for Molecular Brain Science, Department of Life Science and Medical Bioscience, Waseda University, Shinjuku City, Japan.
Atsushi YoshikiExperimental Animal Division, RIKEN BioResource Research Center, Tsukuba, Japan.
Kenya SatoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Wakako KumitaLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
Erika SasakiDepartment of Marmoset Biology and Medicine, Central Institute for Experimental Animals, Kawasaki, Japan.
Shinobu KitazumeDepartment of Clinical Laboratory Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, Japan.
Per NilssonDivision of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
Bengt WinbladDivision of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.
Takashi SaitoDepartment of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Nobuhisa IwataDepartment of Genome-Based Drug Discovery and Leading Medical Research Core Unit, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Takaomi C SaidoLaboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Japan.
RIKEN Center for Brain Science · JPKarolinska Institutet · SEWaseda University · JPCentral Institute for Experimental Animals · JPFukushima Medical University · JPNagasaki University · JPNagoya City University · JPNagoya University · JPRIKEN BioResource Research Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 1995, more than 100 transgenic (Tg) mouse models of Alzheimer's disease (AD) have been generated in which mutant amyloid precursor protein (APP) or APP/presenilin 1 (PS1) cDNA is overexpressed (

Indexed as

Alzheimer’s diseaseamyloid – betaamyloidosismouse modelnon-human primate (NHP)somatostatintau propagation

Identifiers

PMID35431779
PMCPMC9009508
OpenAlexW4220790273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.